Literature DB >> 11519507

Idiopathic pulmonary fibrosis.

T J Gross1, G W Hunninghake.   

Abstract

Idiopathic pulmonary fibrosis is a rapidly progressive illness of unknown cause characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Treatment at present remains largely supportive, with evidence that patients' satisfaction and survival may be improved by referral to centers specializing in the evaluation of interstitial lung diseases. Although no drug therapy has clearly been demonstrated to benefit patients with idiopathic pulmonary fibrosis, a number of novel investigational agents hold promise for future study. Given the poor prognosis associated with idiopathic pulmonary fibrosis, patients should be referred to regional centers of expertise for enrollment in therapeutic clinical trials or for lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519507     DOI: 10.1056/NEJMra003200

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  298 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.

Authors:  Rishi B Patel; Sainath R Kotha; Lynn A Sauers; Smitha Malireddy; Travis O Gurney; Niladri N Gupta; Terry S Elton; Ulysses J Magalang; Clay B Marsh; Boyd E Haley; Narasimham L Parinandi
Journal:  Toxicol Mech Methods       Date:  2012-06       Impact factor: 2.987

Review 3.  The bone marrow leaves its scar: new concepts in pulmonary fibrosis.

Authors:  Sarah E Dunsmore; Steven D Shapiro
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-2002. A 56-year-old man with rapidly worsening dyspnea.

Authors:  Michelle Ng Gong; Eugene J Mark
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

Review 5.  Pulmonary fibrosis: thinking outside of the lung.

Authors:  Stavros Garantziotis; Mark P Steele; David A Schwartz
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 6.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

9.  Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.

Authors:  Corrine R Kliment; Judson M Englert; Bernadette R Gochuico; Guoying Yu; Naftali Kaminski; Ivan Rosas; Tim D Oury
Journal:  J Biol Chem       Date:  2008-12-09       Impact factor: 5.157

10.  Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Hakan Parlakpinar; Alaadin Polat; Elif Taslidere; Nigar Vardi; Ediz Sarihan; Hilal Ermis; Kevser Tanbag
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.